TABLE 3.
Characteristics of various plasmids harboring ESBLs
| Plasmid | ESBL gene | Clinical strain(s) | Estimated size (kb) | Additional non-beta-lactam resistance transferred to DH10Ba | Region submitting the strainb |
|---|---|---|---|---|---|
| pT52-1a | TEM-52 | ESBL 424 | 146 | GM | W (site 1) |
| pT52-2a | TEM-52 | ESBL 140 | 81 | GM/TB | E (site 2) |
| pT115-1a | TEM-115 | ESBL 187, ESBL 218 | 70 | GM/TB | E (site 3, both strains) |
| pT120-1a | TEM-120 | ESBL 511 | 72 | GM | E (site 3) |
| pC14-1a | CTX-M-14 | ESBL 1 | 68 | None | E (site 4) |
| pC14-1b | CTX-M-14 | ESBL 144 | 75 | None | E (site 2) |
| pC14-1c | CTX-M-14 | ESBL 154 | 59 | None | E (site 2) |
| pC14-2a | CTX-M-14 | ESBL 138 | 73 | None | E (site 2) |
| pC14-3a | CTX-M-14 | ESBL 326 | 147 | AK/GM/TB/TS | W (site 5) |
| pC14-4a | CTX-M-14 | ESBL 339 | 84 | TS | W (site 5) |
| pC14-5a | CTX-M-14 | ESBL 351 | 80 | None | W (site 5) |
| pC14-6a | CTX-M-14 | ESBL 512 | 64 | None | E (site 3) |
| pC15-1a | CTX-M-15 | ESBL 304 | 72 | GM/TB | W (site 5) |
| pC15-1b | CTX-M-15 | ESBL 35 | 77 | GM/TB | W (site 5) |
| pC15-2a | CTX-M-15 | ESBL 123 | 111 | TS | W (site 5) |
| pC15-2b | CTX-M-15 | ESBL 480 | 131 | GM/TB | E (site 4) |
| pC15-3a | CTX-M-15 | ESBL 3 | 70 | None | E (site 4) |
| pC15-3b | CTX-M-15 | ESBL 122 | 81 | None | W (site 5) |
| pS2a-1a | SHV-2a | ESBL 32 | 96 | TS | W (site 5) |
| pS2a-2a | SHV-2a | ESBL 435 | 67 | TS | W (site 1) |
| pS2a-2b | SHV-2a | ESBL 338 | 71 | TS | W (site 5) |
| pS2a-2c | SHV-2a | ESBL 344 | 68 | TS | W (site 5) |
| pS2a-3a | SHV-2a | ESBL 333 | 65 | None | W (site 5) |
| pS2a-4a | SHV-2a | ESBL 85 | 129 | TS | W (site 5) |
| pS2a-5a | SHV-2a | ESBL 97 | 109 | None | W (site 5) |
| pS2a-6a | SHV-2a | ESBL 53 | 131 | TS | W (site 5) |
| pS5-1a | SHV-5 | ESBL 261 | 80 | TB/TS | W (site 6) |
| pS5-1b | SHV-5 | ESBL 12 | 85 | TB/TS | E (site 4) |
| pS5-1c | SHV-5 | ESBL 10 | 84 | TB/TS | E (site 4) |
| pS12-1a | SHV-12 | ESBL 131 | 115 | TB/TS | W (site 5) |
| pS12-2a | SHV-12 | ESBL 229 | 174 | AK/TB/TS | W (site 7) |
| pS12-3a | SHV-12 | ESBL 292 | 159 | GM/TB/TS | E (site 8) |
| pS12-4a | SHV-12 | ESBL 444 | 101 | GM/TB | W (site 7) |
| pS12-5a | SHV-12 | ESBL 182 | 173 | None | E (site 3) |
| pS12-6a | SHV-12 | ESBL 364 | 107 | AK/GM/TB | W (site 5) |
| pS12-6b | SHV-12 | ESBL 513 | 109 | AK/GM/TB | E (site 3) |
| pS12-7a | SHV-12 | ESBL 320 | 115 | TS | W (site 5) |
| pS12-8a | SHV-12 | ESBL 5 | 79 | TB | E (site 4) |
| pS12-9a | SHV-12 | ESBL 184 | 79 | GM | E (site 3) |
| pS12-9b | SHV-12 | ESBL 200 | 74 | None | E (site 3) |
| pS12-10a | SHV-12 | ESBL 18 | 115 | None | E (site 8) |
| pS12-11a | SHV-12 | ESBL 1 | 83 | None | E (site 4) |
| pS12-12a | SHV-12 | ESBL 264 | 133 | None | W (site 6) |
| pS12-13a | SHV-12 | ESBL 8 | 157 | GM | E (site 4) |
| pS12-14a | SHV-12 | ESBL 152 | 60 | GM/TB | E (site 2) |
| pS12-15a | SHV-12 | ESBL 93 | 79 | TB | W (site 5) |
| pS12-16a | SHV-12 | ESBL 457, ESBL 460 | 208 | GM/TS | E (site 9, both strains) |
| pS12H3-1a | SHV-12 | ESBL 17, ESBL 272, ESBL 277 | 141 | GM/TS | E (site 8, all three strains) |
| pS12H3-1b | SHV-12 | ESBL 271 | 135 | GM/TS | E (site 8) |
| pS12H3-1c | SHV-12 | ESBL 69 | 131 | TS | W (site 5) |
| pS12H3-1d | SHV-12 | ESBL 275 | 128 | GM/TS | E (site 8) |
| pS12H3-1e | SHV-12 | ESBL 273 | 139 | TS | E (site 8) |
| pS30-1a | SHV-30 | ESBL 290, ESBL 295 | 64 | GM/TB | E (site 8, both strains) |
a
Determined by using Vitek GNS-121 panels. AK, amikacin; GM, gentamicin; TB, tobramycin; TS, trimethoprim-sulfamethoxazole; CP, ciprofloxacin; LV, levofloxacin; NF, nitrofurantoin.
b
W, west; E, east.